Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability: an open-label, single-arm, singlecenter, pilot study
Not Applicable
Recruiting
- Conditions
- hepatic encephalopathy
- Registration Number
- JPRN-UMIN000032308
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The patient with the change of the medicine for the hepatic encephalopathy within agreement acquisition three months ago. The patient who corresponds to a taboo listed in the attached document of rifaximine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The amount of change from a baseline of blood endotoxin activity in four weeks.
- Secondary Outcome Measures
Name Time Method